Fennec Pharmaceuticals Inc. (FENC)
FENC Stock Price Chart
Explore Fennec Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze FENC price movements and trends.
FENC Company Profile
Discover essential business fundamentals and corporate details for Fennec Pharmaceuticals Inc. (FENC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
15 Sept 2017
Employees
32.00
Website
https://www.fennecpharma.comCEO
Jeffrey S. Hackman
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
FENC Financial Timeline
Browse a chronological timeline of Fennec Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.16, while revenue estimate is $13.43M.
Earnings released on 14 Aug 2025
EPS came in at -$0.11 falling short of the estimated -$0.06 by -83.33%, while revenue for the quarter reached $9.65M , beating expectations by +0.94%.
Earnings released on 13 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.12 by +66.67%, while revenue for the quarter reached $8.75M , missing expectations by -3.23%.
Earnings released on 10 Mar 2025
EPS came in at -$0.06 falling short of the estimated $0.56 by -110.71%, while revenue for the quarter reached $7.93M , beating expectations by +1.59%.
Earnings released on 7 Nov 2024
EPS came in at -$0.21 falling short of the estimated -$0.13 by -61.54%, while revenue for the quarter reached $6.97M , missing expectations by -12.93%.
Earnings released on 13 Aug 2024
EPS came in at -$0.20 falling short of the estimated $0.06 by -433.33%, while revenue for the quarter reached $7.26M , missing expectations by -34.28%.
Earnings released on 14 May 2024
EPS came in at $0.47 surpassing the estimated $0.26 by +80.77%, while revenue for the quarter reached $25.38M , beating expectations by +34.41%.
Earnings released on 21 Mar 2024
EPS came in at -$0.10 falling short of the estimated -$0.02 by -400.00%, while revenue for the quarter reached $9.74M , beating expectations by +12.28%.
Earnings released on 6 Nov 2023
EPS came in at -$0.07 surpassing the estimated -$0.11 by +36.36%, while revenue for the quarter reached $6.52M , missing expectations by -19.17%.
Earnings released on 3 Aug 2023
EPS came in at -$0.21 falling short of the estimated -$0.18 by -16.67%, while revenue for the quarter reached $3.33M , missing expectations by -47.47%.
Earnings released on 11 May 2023
EPS came in at -$0.23 falling short of the estimated -$0.21 by -9.52%, while revenue for the quarter reached $1.68M , missing expectations by -9.35%.
Earnings released on 30 Mar 2023
EPS came in at -$0.26 falling short of the estimated -$0.24 by -8.33%, while revenue for the quarter reached $1.54M , beating expectations by +107.43%.
Earnings released on 11 Nov 2022
EPS came in at -$0.31 falling short of the estimated -$0.17 by -82.35%.
Earnings released on 12 Aug 2022
EPS came in at -$0.19 falling short of the estimated -$0.10 by -90.00%.
Earnings released on 12 May 2022
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
Earnings released on 28 Feb 2022
EPS came in at -$0.18 falling short of the estimated $3.52 by -105.11%.
Earnings released on 10 Nov 2021
EPS came in at -$0.16 surpassing the estimated -$0.18 by +11.11%.
Earnings released on 10 Aug 2021
EPS came in at -$0.15 surpassing the estimated -$0.19 by +21.05%.
Earnings released on 13 May 2021
EPS came in at -$0.18 falling short of the estimated -$0.12 by -50.00%.
Earnings released on 30 Mar 2021
EPS came in at -$0.13 surpassing the estimated -$0.19 by +31.58%, while revenue for the quarter reached $170.00K .
Earnings released on 16 Nov 2020
EPS came in at -$0.24 falling short of the estimated -$0.18 by -33.33%.
FENC Stock Performance
Access detailed FENC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.